MedTrace Logo

Assessing Normal Multichannel Intraluminal Impedance (MII)-pH Parameters for Today's Population

NCT01566383 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2017-02-23

No results posted yet for this study

Summary

The normal values of a Multichannel Intraluminal Impedance (MII)-pH study can vary between ages, gender, race and different values of body mass index (BMI). This fact can cause new modifications in the normal values such as making new scales for different age groups or BMI groups.

Our aim is to find the normal esophageal MII-pH parameter ranges in volunteers who never experienced reflux related symptoms and are in between the same ranges of age and BMI of our gastroesophageal reflux disease (GERD) patient population.

Conditions

  • Identify Normal MII-pH Parameters

Interventions

PROCEDURE

24-hr pH monitoring

Visit 1 The following will be done: * A medical history including review of your current drugs; * Collection of demographic information; * A manometry, before the 24-hour pH testing, to find the junction between the esophagus and stomach; * 24-hour pH testing will be done Visit 2 You will return to the clinic 24 hours after the visit 1 and the following will occur: * The catheter will be removed from your nose; and * You will return the recording device

Sponsors & Collaborators

  • Vanderbilt University Medical Center

    lead OTHER

Principal Investigators

  • Michael F Vaezi, MD, PhD · Vanderbilt University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
33 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2013-08-27
Completion
2013-08-27

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01566383 on ClinicalTrials.gov